Skip to main content
. 2021 Oct 13;12:738788. doi: 10.3389/fimmu.2021.738788

Table 3.

Univariate and multivariate analysis of variables associated with clinical remission at month-12.

Variables Remission at month-12 (n=41) No remission at month-12 (n=27) Univariate P-value Multivariate P-value
Age (years) 60.0 [50.0–68.0] 56.0 [42.0–67.0] 0.3
Gender (Female/Male) 11/30 8/19 1
Weight (kg) at baseline* 71.5 [66.0–82.0] 78.0 [74.0–89.2] 0.06 0.02
UP (g/d) at baseline* 5.2 [4.0–7.1] 7.4 [5.6–11.9] 0.005 0.2
Serum creatinine (µmol/L) at baseline 118 [87–149] 123 [87–184] 0.4
Serum albumin (g/L) at baseline* 24.8 [20.2–29.4] 16.0 [13.0–22.1] 0.001 0.7
CD19+ count (cell/µL) at baseline 186.0 [125.0–285.0] 185.0 [88.7–263.8] 0.9
CD19+ count (cell/µL) at month-3* 0.0 [0.0–2.7] 3.0 [1.0–16.0] 0.005 0.9
Etiology 0.8
 Anti-PLA2R1-associated pMN 37 (90%) 25 (93%)
 Anti-THSD7A-associated pMN 1 (2%) 1 (3%)
 Double negative patients 3 (8%) 1 (3%)
Anti-PLA2R1 Ab titer (RU/mL) at baseline* 86 [21–188] 226 [110–561] 0.001 0.5
Patient with RTX <2µg/mL at month-3* 16 (26%) 22 (85%) 0.001 0.01

*Variables with p < 0.1 in univariate analysis tested into the multivariate logistic regression model.

Anti-PLA2R1 Ab, anti-Phospholipase A2 Receptor 1 antibody; Anti-THSD7A Ab, anti-Thrombospondin Type 1 Domain Containing 7A antibody; pMN, primary membranous nephropathy; RTX, rituximab; UP, 24-hour urinary protein excretion.